

# Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](http://FDI Lab - SciCrunch.org) on Apr 24, 2025

## CDK12 Antibody

RRID:AB\_2715688

Type: Antibody

---

### Proper Citation

(Cell Signaling Technology Cat# 11973, RRID:AB\_2715688)

---

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2715688](http://antibodyregistry.org/AB_2715688)

**Proper Citation:** (Cell Signaling Technology Cat# 11973, RRID:AB\_2715688)

**Target Antigen:** CDK12

**Host Organism:** rabbit

**Clonality:** polyclonal

**Comments:** Applications: W, IP

**Antibody Name:** CDK12 Antibody

**Description:** This polyclonal targets CDK12

**Target Organism:** Human, Monkey

**Antibody ID:** AB\_2715688

**Vendor:** Cell Signaling Technology

**Catalog Number:** 11973

**Alternative Catalog Numbers:** 11973S

**Record Creation Time:** 20231110T033810+0000

**Record Last Update:** 20240725T032325+0000

---

### Ratings and Alerts

No rating or validation information has been found for CDK12 Antibody.

No alerts have been found for CDK12 Antibody.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 7 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [FDI Lab - SciCrunch.org](#).

Polenkowski M, et al. (2023) THOC5 complexes with DDX5, DDX17, and CDK12 to regulate R loop structures and transcription elongation rate. *iScience*, 26(1), 105784.

Dieter SM, et al. (2021) Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer. *Cell reports*, 36(3), 109394.

Sivakumaren SC, et al. (2020) Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors. *Cell chemical biology*, 27(5), 525.

Lv L, et al. (2020) Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation. *eLife*, 9.

Iniguez AB, et al. (2018) EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. *Cancer cell*, 33(2), 202.

Gao Y, et al. (2018) Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. *Cell chemical biology*, 25(2), 135.

Wu YM, et al. (2018) Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. *Cell*, 173(7), 1770.